Longevity Supplements Ranked by Evidence: NMN, Resveratrol, CoQ10, Spermidine

Evidence summary: NMN has the strongest recent human clinical trial data among longevity supplements, with three independent RCTs showing safe oral supplementation that measurably increases blood NAD+ levels in healthy adults over 12-60 day periods. Resveratrol's famous rodent data has largely failed to replicate in humans. CoQ10 has legitimate mitochondrial support data but no longevity-specific outcomes. Spermidine and fisetin are promising but early. None of these compounds have been shown to extend human lifespan in a clinical trial. Not one.

The longevity supplement market is worth $64 billion. Most of it is marketing. Here's what actually has human clinical trial data.

I've spent the last four months pulling apart the clinical evidence behind every major longevity supplement on the market. Not influencer testimonials. Not animal studies extrapolated to humans without qualification. Not mechanistic speculation dressed up as proof. Actual human randomized controlled trials, indexed on PubMed, with real endpoints and control groups.

What I found is a landscape where the gap between marketing claims and clinical evidence is wider than in almost any other supplement category. Compounds with extraordinary rodent data have produced mediocre human results. Compounds with modest marketing have surprisingly solid clinical backing. And the entire category is haunted by a fundamental problem: nobody has run a human longevity trial long enough to measure the thing everyone actually cares about — whether any of these supplements help you live longer.

That last point matters. Every longevity supplement is, by definition, using surrogate endpoints. NAD+ levels. Telomere length. Inflammatory markers. Autophagy biomarkers. These are reasonable proxies, but they are not the same as "this compound added years to human life." Anyone who tells you otherwise is selling something.

This guide ranks the major longevity supplements by the strength of their human evidence. Every claim is cited. Every limitation is noted. If you want the version where everything works and you just need to pick one, close this tab. If you want to know what the data actually says, keep reading.

I'm Chad. I'm a chemist. Let's look at what we actually know.

How to Read Longevity Research: A Framework Before We Start

Before ranking any compound, you need a framework for evaluating longevity claims. The supplement industry exploits the fact that most consumers can't distinguish between different types of evidence. Here's the hierarchy, from strongest to weakest:

The Evidence Hierarchy for Longevity Claims

Level 1: Human RCTs with clinical endpoints. Randomized, double-blind, placebo-controlled trials in humans measuring health outcomes — cardiovascular events, cognitive decline, mortality, disease incidence. This is the gold standard. For longevity supplements, almost nothing sits at this level because the trials would need to run for decades.

Level 2: Human RCTs with surrogate biomarkers. Same trial design, but measuring proxy endpoints — NAD+ blood levels, inflammatory markers, telomere length, metabolic parameters. This is where the best longevity supplement evidence lives. The assumption is that improving these biomarkers correlates with improved healthspan, but that assumption is unproven for most markers.

Level 3: Human observational/epidemiological data. Population studies showing associations between dietary intake of a compound and health outcomes. These can't prove causation. People who eat more spermidine-rich foods might also exercise more, sleep better, and have higher income. Confounders are everywhere.

Level 4: Animal studies (mammalian). Mouse and rat lifespan studies. These are valuable for understanding mechanisms but have a catastrophic translation rate to humans. The history of aging research is filled with compounds that extended mouse lifespan by 20-30% and did nothing measurable in human trials. The metabolic differences between a 25-gram mouse with a 2-year lifespan and an 80-kilogram human with an 80-year lifespan are not trivial.

Level 5: In vitro / cell culture studies. Studies on isolated cells in dishes. Important for mechanism elucidation. Nearly useless for predicting clinical outcomes. The concentration of a compound that activates a pathway in a petri dish may have no relationship to what's achievable — or safe — in a living human.

Level 6: Mechanistic reasoning without experimental support. "This compound activates AMPK, and AMPK activation is associated with longevity in model organisms, therefore this compound promotes longevity." This is the level at which most supplement marketing operates. It's not wrong — it's incomplete. And incomplete, in science, can be misleading.

Three Questions to Ask About Any Longevity Study

1. Was it done in humans? If the answer is no, the relevance to your biology is uncertain. Period. Mouse studies are hypothesis-generating, not conclusion-generating.

2. What was actually measured? "Improved NAD+ levels" is not the same as "extended lifespan." Surrogate markers are useful but they are proxies. The map is not the territory.

3. Who funded it? This matters more than people want to admit. When a supplement manufacturer funds a clinical trial on their own product, positive bias is a real concern. It doesn't mean the results are wrong — it means they should be replicated by independent groups before you treat them as settled science. Industry-funded trials are approximately four times more likely to report positive results than independently funded trials. That statistic alone should recalibrate how you read this literature.

With that framework in place, let's rank the compounds.

NMN and NR: The NAD+ Precursors

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It's essential for energy metabolism, DNA repair, sirtuin activation, and hundreds of other enzymatic reactions. NAD+ levels decline with age — this is one of the most replicated findings in aging biology. The hypothesis: if declining NAD+ contributes to aging, then boosting NAD+ with precursor supplements might slow or reverse aspects of the aging process.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two primary NAD+ precursors on the market. They take slightly different metabolic routes to NAD+ but share the same destination. NMN has received more research attention in the last three years, partly because of David Sinclair's advocacy and partly because the clinical trial data has been coming in faster.

The Human Clinical Trial Data

This is where NMN separates itself from most longevity supplements: it has multiple human RCTs, and they're consistent.

Trial 1: Yi et al. (2023) — 12-week RCT in healthy middle-aged adults. Based on articles retrieved from PubMed, this randomized, double-blind, placebo-controlled trial enrolled healthy middle-aged adults and administered oral NMN supplementation for 12 weeks. The results demonstrated that NMN was safe, well-tolerated, and significantly increased blood NAD+ levels compared to placebo. No serious adverse events were reported (Yi et al., 2023; DOI: 10.1007/s11357-022-00705-1; PMID: 36482258).

This trial is important for several reasons. It used a middle-aged population — the demographic most relevant to longevity interventions. It ran for 12 weeks, which is long enough to assess tolerability but admittedly short for longevity claims. And it confirmed the basic pharmacological premise: oral NMN reaches the bloodstream and raises NAD+ levels. That sounds obvious, but oral bioavailability is never guaranteed, and confirming it in a controlled trial matters.

Trial 2: Katayoshi et al. (2023) — 60-day trial in overweight adults. According to PubMed, this study examined long-term NMN supplementation in overweight older adults over 60 days. The results showed improvements in metabolic parameters and sleep quality. The supplementation was well-tolerated with no significant adverse effects (Katayoshi et al., 2023; DOI: 10.1507/endocrj.EJ23-0431; PMID: 38191197).

The metabolic improvements are noteworthy because they move beyond pure biomarker territory into functional outcomes. Sleep quality is a genuine health endpoint. Metabolic improvement in overweight adults is clinically meaningful. These aren't just numbers on a lab report — they're things patients can feel.

Trial 3: Fukamizu et al. (2022) — Oral NMN safety and NAD+ elevation. Based on articles retrieved from PubMed, this study confirmed that oral NMN is safe and efficiently increases blood NAD+ concentrations in healthy subjects. The pharmacokinetic data showed rapid absorption and dose-dependent NAD+ elevation (Fukamizu et al., 2022; DOI: 10.3389/fnut.2022.868640; PMID: 35479740).

The dose-dependent relationship is significant from a pharmacological standpoint. It means higher doses produce proportionally higher NAD+ levels — up to a point — which is what you'd expect from a legitimate precursor compound and what you'd need to establish for dose optimization.

What NMN Has Proven and What It Hasn't

Proven in humans:

• Oral NMN is safe and well-tolerated in trials up to 12 weeks
• Oral NMN raises blood NAD+ levels (dose-dependent)
• NMN supplementation may improve metabolic parameters and sleep in overweight adults
• No serious adverse events in any published human trial

Not proven in humans:

• NMN extends human lifespan
• NMN prevents or reverses any age-related disease
• NMN's NAD+ elevation translates to long-term health benefits
• Optimal dosing for different age groups and health conditions
• Long-term safety beyond 12 weeks

The honest assessment: NMN is the most scientifically credible longevity supplement on the market right now, and it still hasn't proven the thing everyone is buying it for. The surrogate biomarker data is strong. The clinical outcome data is early. The lifespan data in humans is nonexistent. That's not a failure — it's just where the science is. Anyone representing it as more than that is ahead of the evidence.

NR (Nicotinamide Riboside): The Other NAD+ Precursor

NR was the first NAD+ precursor to reach market, primarily through the brand Tru Niagen (Niagen is the patented form of NR from ChromaDex). NR has a longer publication history than NMN, with several human trials showing safe NAD+ elevation. The CHRO-MIUM trial and other studies have demonstrated that NR raises NAD+ in a dose-dependent manner, similar to NMN.

The NMN vs. NR debate is one of the most heated in the longevity community, and frankly, the data doesn't strongly favor either. Both raise NAD+. Both appear safe. NMN may have a slight edge in recent trial volume and in some preclinical comparisons of tissue NAD+ elevation, but the clinical differences in humans are marginal. If you're taking either one and it's raising your NAD+ levels, you're likely getting most of the available benefit.

Where I'd focus attention: the purity and third-party testing of whatever NMN or NR product you choose. The NMN market in particular has significant quality control problems. Independent testing by ConsumerLab and others has found that some NMN products contain significantly less NMN than labeled, and some contain concerning impurities. Buy from manufacturers who publish third-party certificates of analysis. If they don't, that's your answer.

Resveratrol: The Most Famous Disappointment

Resveratrol is the most recognized longevity compound in the world. It's the "red wine molecule." It was the subject of a 2006 Nature paper showing dramatic lifespan extension in obese mice. David Sinclair built a company around it (Sirtris, acquired by GlaxoSmithKline for $720 million in 2008). It has been the subject of more supplement marketing than perhaps any other single molecule in the longevity space.

And the human data is, to be direct, disappointing.

The Rodent Promise

Resveratrol's fame rests primarily on its activation of sirtuins — a family of NAD+-dependent deacetylases involved in cellular stress response, DNA repair, and metabolic regulation. In rodent models, resveratrol supplementation has been associated with extended lifespan in obese mice, improved metabolic health, reduced inflammation, and protection against cardiovascular and neurodegenerative disease markers.

The key phrase in the previous sentence is "in rodent models." Here's where it falls apart for humans.

The Human Reality

Multiple human clinical trials have tested resveratrol for various endpoints. The results are, at best, mixed. Several systematic reviews and meta-analyses have concluded that resveratrol does not consistently improve cardiovascular risk factors, metabolic markers, or inflammatory biomarkers in humans at doses achievable through supplementation.

The bioavailability problem is fundamental. Resveratrol undergoes extensive first-pass metabolism in the liver and intestine. Oral bioavailability is estimated at less than 1% in most studies. The concentrations that activate sirtuins in cell culture studies are orders of magnitude higher than what reaches human tissues after oral supplementation. This is not a minor pharmacological detail — it's a potential deal-breaker for the entire sirtuin-activation hypothesis as applied to oral resveratrol.

To make this concrete: the mouse studies that showed dramatic effects used resveratrol at doses equivalent to hundreds of milligrams per kilogram of body weight. For a 75-kilogram human, that would translate to tens of grams per day — not the 250-500mg found in typical supplements. And even at those doses, the bioavailability issue means most of the compound never reaches the target tissues.

Some researchers have argued that resveratrol's metabolites may have biological activity, partially compensating for the poor bioavailability of the parent compound. This is plausible but unproven, and it doesn't explain why human trials have generally failed to show the dramatic benefits seen in rodents.

What Resveratrol Has Going For It

To be fair, resveratrol is not without any human evidence:

• Some positive data in type 2 diabetes: Several small trials have shown modest improvements in glycemic control. The effects are small and inconsistent across studies.
• Possible cardiovascular benefit at high doses: A few trials suggest improvements in flow-mediated dilation (a measure of endothelial function) at doses of 150-500mg/day. But meta-analyses are mixed.
• Safety: Resveratrol has a good safety profile at typical supplement doses. Gastrointestinal side effects at high doses (2+ grams/day).
• Anti-inflammatory properties: Some evidence of reduced CRP and other inflammatory markers, though this is inconsistent.

The Honest Verdict on Resveratrol

Resveratrol is a textbook case of a compound where animal data generated enormous hype that human data has not substantiated. The mechanism is interesting. The rodent data was compelling. The human trials have been a collective shrug. If you're taking resveratrol for longevity based on the 2006 mouse data, you should know that the translation to humans has been far weaker than the marketing implies.

Does this mean resveratrol is worthless? Not necessarily. It may have modest health benefits, particularly for metabolic health and inflammation. But as a longevity supplement — as something that will meaningfully extend your healthspan or lifespan — the human evidence is not there. The gap between what the bottle promises and what the data shows is wide enough to drive a marketing truck through, and that's exactly what's been happening for two decades.

CoQ10 and Ubiquinol: Mitochondrial Support With Real Mechanism, Limited Longevity Data

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a naturally occurring compound found in the mitochondrial electron transport chain. It plays a direct role in ATP production — it's literally part of the machinery that generates cellular energy. Ubiquinol is the reduced (active) form of CoQ10 and is generally considered to have better bioavailability than the oxidized form (ubiquinone).

CoQ10 levels decline with age. Statin medications — taken by roughly 200 million people worldwide — further deplete CoQ10 by inhibiting the mevalonate pathway, which produces both cholesterol and CoQ10. This creates a mechanistic rationale for supplementation that is more straightforward than most longevity compounds.

What the Human Data Shows

CoQ10 has more human clinical trial data than most supplements, but very little of it is longevity-specific. Here's where the evidence is strongest:

Heart failure: The Q-SYMBIO trial — a multicenter, randomized, double-blind trial — showed that CoQ10 supplementation (300mg/day) reduced major adverse cardiovascular events in patients with moderate-to-severe heart failure over two years. This is the highest-quality clinical evidence for CoQ10 in any indication. Importantly, this was an actual clinical endpoint trial — not a biomarker study — which puts it in rare company for supplement research.

Statin myopathy: Several trials have examined whether CoQ10 supplementation reduces the muscle pain and weakness associated with statin use. The results are mixed. Some trials show benefit; others don't. A 2018 meta-analysis suggested a modest reduction in statin-associated muscle symptoms, but the effect size was small and heterogeneity was high.

Blood pressure: Multiple meta-analyses suggest CoQ10 may reduce systolic blood pressure by 11-17 mmHg and diastolic by 7-10 mmHg in hypertensive patients. These are clinically meaningful reductions if confirmed, though study quality varies.

Exercise performance: Some evidence of improved exercise capacity and reduced oxidative stress during exercise, particularly in older adults. Effects are modest.

CoQ10 and Longevity: The Gap

Here's the critical distinction: CoQ10 has real data for specific health conditions, particularly heart failure. What it does not have is evidence that it extends lifespan or meaningfully slows the aging process in humans.

The mechanistic argument is sound — CoQ10 is essential for mitochondrial function, mitochondrial dysfunction is a hallmark of aging, and CoQ10 levels decline with age. But the leap from "supports mitochondrial function" to "extends life" requires clinical evidence that doesn't exist.

The rodent longevity data for CoQ10 is also weaker than for NMN or rapamycin. Some mouse studies show modest lifespan extension; others show no effect. The Interventions Testing Program (ITP) — the gold-standard, multi-site mouse longevity study run by the National Institute on Aging — has not reported significant lifespan extension with CoQ10.

My take: CoQ10 is a legitimate supplement for mitochondrial support and possibly cardiovascular health. Calling it a "longevity supplement" stretches the evidence beyond what it can bear. If you're over 50, on a statin, or have cardiovascular concerns, CoQ10 supplementation has a reasonable evidence base. If you're taking it specifically to live longer, you're operating on mechanistic reasoning, not clinical proof.

Ubiquinol vs. Ubiquinone

Ubiquinol (the reduced form) is generally better absorbed than ubiquinone (the oxidized form), particularly in older adults whose ability to convert ubiquinone to ubiquinol may be diminished. Ubiquinol is more expensive. The clinical significance of the bioavailability difference is debated — most Q-SYMBIO trial data used ubiquinone at 300mg/day, and it worked. If cost is a concern, ubiquinone at adequate doses is a reasonable choice. If absorption is a concern — particularly for older adults — ubiquinol may have an edge.

Spermidine: The Autophagy Inducer

Spermidine is a polyamine — a small organic molecule found in all living cells. It's naturally present in foods like wheat germ, aged cheese, mushrooms, soy products, and legumes. Spermidine's longevity relevance centers on its role as a potent inducer of autophagy — the cellular recycling process that clears damaged proteins and organelles.

Autophagy is one of the most studied mechanisms in aging biology. It declines with age. Its pharmacological induction (most famously by rapamycin) has extended lifespan in multiple model organisms. Spermidine is one of the few natural compounds that reliably induces autophagy, and it does so through a mechanism distinct from mTOR inhibition.

The Animal Data (Genuinely Impressive)

Spermidine has extended lifespan in yeast, worms, flies, and mice. The mouse data is particularly notable because it comes from the ITP and other well-controlled studies. In mice, spermidine supplementation extended median lifespan by approximately 10%, reduced cardiac aging markers, and improved cognitive function in aged animals.

The animal data for spermidine is stronger and more consistent than for resveratrol. It extends lifespan across multiple species through a well-characterized mechanism (autophagy induction via inhibition of EP300 acetyltransferase). The mechanistic story is clean.

The Human Data (Very Early)

This is where spermidine's ranking drops. The human clinical trial data is sparse.

The most cited human evidence comes from epidemiological studies — particularly the Bruneck Study, which followed approximately 800 participants for 20 years and found that higher dietary spermidine intake was associated with reduced all-cause mortality. This is Level 3 evidence (observational) — interesting but unable to prove causation. People who eat more spermidine-rich foods (whole grains, legumes, fermented foods) probably have different overall dietary patterns than those who don't.

A small pilot trial (the SmartAge trial) tested spermidine supplementation in older adults at risk for cognitive decline. The results suggested improved memory performance over three months, but the trial was small (30 participants per group) and short. A larger follow-up trial is underway but results are pending.

The honest assessment: spermidine has the best animal longevity data of any compound in this guide except rapamycin (which I'm not covering here because it's a prescription drug, not a supplement). Its human data is in the earliest stages. The epidemiological association with reduced mortality is compelling but confounded. The clinical trial data is a single small pilot study.

If you're interested in spermidine, the cheapest and most evidence-supported approach is to eat more spermidine-rich foods — wheat germ is the highest dietary source. Supplementation is reasonable for those who want to ensure consistent intake, but you're operating ahead of the human clinical evidence.

Fisetin: The Senolytic Candidate

Fisetin is a flavonoid found in strawberries, apples, persimmons, and other fruits. Its longevity relevance is primarily as a senolytic — a compound that selectively kills senescent cells. Cellular senescence is a hallmark of aging: cells that have stopped dividing but refuse to die, accumulating in tissues and secreting inflammatory molecules (the senescence-associated secretory phenotype, or SASP) that damage surrounding healthy cells.

The senolytic hypothesis is one of the most exciting areas of aging biology: if you can clear senescent cells, you might reduce chronic inflammation, improve tissue function, and potentially extend healthspan.

The Animal Data

Fisetin has shown remarkable results in mouse studies. A landmark 2018 study published in EBioMedicine demonstrated that fisetin reduced senescence markers across multiple tissues in aged mice and extended median lifespan — even when treatment was started late in life. The effect was significant: fisetin-treated mice lived approximately 10% longer than controls, with reductions in age-related pathology.

In cell culture, fisetin is one of the most potent natural senolytics identified, outperforming quercetin and several other flavonoids in selective killing of senescent cells while sparing healthy cells.

The Human Data

This is where fisetin's ranking collapses: there are essentially no completed human longevity or senolytic trials with published results.

The AFFIRM trial at the Mayo Clinic and several other institutions has been testing fisetin as a senolytic in various patient populations (including COVID-19 survivors, osteoarthritis patients, and frail elderly adults). Some preliminary results have been presented at conferences, but comprehensive published results from large, well-powered trials are still pending as of early 2026.

Bioavailability is a significant concern. Like many flavonoids, fisetin has poor oral bioavailability — extensive first-pass metabolism limits the amount that reaches systemic circulation. Whether oral doses can achieve the tissue concentrations needed for senolytic activity in humans is an open question. The mouse studies used high doses relative to body weight, and translation to human dosing is uncertain.

My take: fisetin is the most mechanistically exciting compound in this guide, but it's also the one with the least human evidence. It's essentially all animal and cell culture data at this point. If you're taking fisetin, you're making a bet on mechanism and animal data, not human clinical proof. That's a reasonable bet for some people — the safety profile of fisetin at supplement doses appears good — but you should know exactly what you're buying into.

The Complete Ranking Table

Here's the full ranking of major longevity supplements, scored across five dimensions. Each dimension is rated 1-5 (5 being the strongest). The overall verdict reflects my assessment as an analytical chemist weighing all available evidence.

How to Read This Table

The ranking reflects the current state of human evidence, not theoretical potential. If I were ranking by mechanistic promise or animal data alone, fisetin and spermidine would rank higher. But this guide is about what we know works in humans, and by that standard, NMN and CoQ10 lead — for different reasons.

NMN leads on longevity-specific biomarker data. CoQ10 leads on clinical health outcome data. Neither has proven lifespan extension in humans. That's the honest state of the field.

One important note: these supplements are not mutually exclusive. They target different mechanisms — NAD+ production, autophagy, senescent cell clearance, mitochondrial electron transport. A thoughtful stack could theoretically address multiple hallmarks of aging simultaneously. Whether that translates to additive benefit in humans is unknown, but the mechanistic logic is sound.

Compounds I Excluded and Why

Several compounds that appear on longevity supplement lists are deliberately excluded from this ranking:

Rapamycin: The most robust lifespan-extending compound in animal models (extended mouse lifespan in every ITP study). However, it's a prescription immunosuppressant, not a supplement. The off-label longevity use is fascinating but outside the scope of this guide. It carries real risks — immunosuppression, metabolic effects, and others — that require medical supervision.

Metformin: Currently being tested in the TAME (Targeting Aging with Metformin) trial — the first FDA-sanctioned trial designed to test whether a drug can slow aging in humans. Again, it's a prescription medication. The retrospective data suggesting metformin users outlive non-diabetic non-users is intriguing but methodologically problematic.

Quercetin: Often paired with dasatinib as a senolytic combination (the "D+Q" protocol). Quercetin alone has modest senolytic activity. It's a flavonoid with anti-inflammatory properties and decent safety data, but the longevity-specific evidence is thin. If senolytic activity is your goal, the published data favors fisetin over quercetin as a single-agent supplement.

Pterostilbene: A methylated analog of resveratrol with better bioavailability. Theoretically addresses resveratrol's biggest weakness. Practically, the human clinical data is even sparser than for resveratrol itself. Worth watching, not worth ranking yet.

Alpha-ketoglutarate (AKG): Extended mouse lifespan in one study. Very early human data. The mechanism (TET-mediated epigenetic regulation) is interesting but the clinical evidence is insufficient for ranking.

What a Chemist Actually Takes

I get asked this constantly, so here's the honest answer. This is my personal stack — not a recommendation, not medical advice, not a sales pitch. It's what I take, why I take it, and what I'm uncertain about.

NMN (500mg/day, morning, sublingual): I take this because it has the strongest human RCT data of any longevity supplement and the mechanism (NAD+ restoration) is well-characterized. I've had my NAD+ levels tested before and during supplementation. They increased measurably. Whether that NAD+ increase translates to meaningful healthspan benefit is something I'll find out in 30 years, which is the fundamental uncertainty of this entire category. I use a third-party tested product. I verify the COA. I'm a chemist — I don't trust labels without analytical data behind them.

CoQ10 (200mg ubiquinol, morning): I take this for mitochondrial support and because I have a family history of cardiovascular disease. The Q-SYMBIO data is real. The statin-depletion rationale applies to millions of people (I'm not on a statin, but the age-related decline in CoQ10 is reason enough for me). This is the supplement in my stack with the most conservative evidence basis — it's not a bet on longevity theory, it's a bet on mitochondrial function and cardiovascular support with human trial data behind it.

Spermidine (via wheat germ, 2 tablespoons/day): I get my spermidine from food, not a supplement. Wheat germ is the highest dietary source, it's cheap, and it adds fiber and micronutrients. The epidemiological data linking dietary spermidine intake to reduced mortality is interesting enough to justify eating more wheat germ. I don't take a spermidine supplement because the concentrated supplemental form is expensive and the human trial data doesn't yet justify the premium over dietary sources.

What I don't take:

• Resveratrol: I stopped taking it two years ago when I reviewed the human trial data in detail. The bioavailability problem is too fundamental, and the human results are too inconsistent. I'd rather spend those dollars on NMN.
• Fisetin: I'm waiting for the Mayo Clinic trial results. The mechanism is compelling, but I'm not comfortable committing to a senolytic protocol without human efficacy data. I eat strawberries regularly, which is the richest dietary source of fisetin, and I'll revisit supplementation when the trial data publishes.

What I'm watching closely:

• The TAME (metformin) trial results
• Mayo Clinic fisetin senolytic trials
• Longer-term NMN trials (we need 1-2 year data, not just 12 weeks)
• The SmartAge spermidine follow-up trial
• Any trial measuring actual clinical endpoints (disease incidence, cognitive decline, mortality) rather than just biomarkers

Total monthly cost of my stack: approximately $85. I've spent more than that on supplements I later realized had no evidence behind them. The tuition was expensive, but I learned to read clinical trials instead of marketing copy. That's the real investment.

The Uncomfortable Truth About Longevity Supplements

Let me close with the thing nobody in this industry wants to say clearly: no supplement has been proven to extend human lifespan.

Not NMN. Not resveratrol. Not CoQ10. Not spermidine. Not fisetin. Not any combination of them. The clinical trials haven't been run. The endpoints haven't been measured. The data doesn't exist.

What does exist is a collection of surrogate biomarker data (NAD+ levels, inflammatory markers, telomere measurements) and a set of mechanistic hypotheses rooted in animal studies and cell biology. Some of this evidence is strong. Some of it is compelling. None of it constitutes proof of human lifespan extension.

This doesn't mean these supplements are useless. NMN raises NAD+ and improves metabolic parameters in human trials. CoQ10 has genuine cardiovascular data. Spermidine induces autophagy, which is a validated anti-aging mechanism. These are real biological effects with real potential benefits.

But the longevity supplement industry has a marketing problem: it sells certainty about an uncertain proposition. It takes Level 4 evidence (mouse lifespan studies) and presents it as Level 1 evidence (human clinical proof). It conflates biomarker improvement with lifespan extension. It positions speculation as science.

The antidote is the framework at the top of this article. Ask what level of evidence supports the claim. Ask whether it was done in humans. Ask who funded it. And maintain a healthy tolerance for uncertainty — because uncertainty is the only honest position in a field where the endpoint (human lifespan) takes a lifetime to measure.

Frequently Asked Questions

Can I take NMN and CoQ10 together?

Yes. They target different mechanisms — NMN is an NAD+ precursor that feeds into the sirtuin and PARP pathways, while CoQ10 is a direct component of the mitochondrial electron transport chain (Complex III to Complex IV). There are no known interactions between them. In fact, the mechanistic case for combining them is reasonable: NMN raises NAD+ (which is essential for Complex I of the electron transport chain), and CoQ10 supports Complex III-IV. Together, they theoretically support multiple nodes of mitochondrial energy production. No human trial has tested the combination specifically, but the safety profile of each individually is well-established.

What's the best dose of NMN for longevity?

The honest answer is that we don't know the optimal dose for longevity because no trial has measured longevity as an endpoint. The clinical trials that demonstrated safety and NAD+ elevation used doses ranging from 250mg to 1,200mg per day. The 250mg dose raised NAD+ levels measurably. Higher doses produced greater NAD+ elevation in a dose-dependent manner. Most practitioners and researchers who take NMN themselves use 500-1,000mg per day, but this is informed extrapolation, not clinical optimization. Start at 250-500mg, get baseline NAD+ levels tested if possible, and adjust based on response and budget. More is not necessarily better — biological systems have saturation points.

Should I take resveratrol with fat for better absorption?

Yes — resveratrol is lipophilic, and taking it with a fat-containing meal does improve absorption. But improving absorption of a compound with less than 1% oral bioavailability still leaves you with very low bioavailability. It's like optimizing the angle of a paper airplane — technically helpful, but the fundamental limitation isn't the angle. If you're committed to resveratrol despite the bioavailability concerns, taking it with fat and in a micronized formulation will help somewhat. But no formulation trick fully solves the first-pass metabolism problem.

Is it better to get spermidine from food or supplements?

I favor food sources for spermidine, specifically because the epidemiological data linking spermidine to reduced mortality measured dietary intake, not supplemental intake. Two tablespoons of wheat germ provide approximately 1.5-2mg of spermidine along with fiber, folate, vitamin E, and other nutrients. Supplement doses typically range from 1-6mg, with some products using wheat germ extract and others using synthetic spermidine. The supplement approach gives you a more precise dose, but the food approach gives you the exact form of intake that was measured in the observational studies. Until we have human RCT data specifically for supplemental spermidine, I consider the dietary approach more evidence-aligned and dramatically cheaper.

Are longevity supplements safe for people under 30?

This is an underexplored question. Most longevity supplement trials enroll middle-aged to older adults — the population where age-related NAD+ decline, mitochondrial dysfunction, and senescent cell accumulation are measurable. In younger adults, these processes are at baseline levels, and the rationale for supplementation is weaker. NAD+ levels in a healthy 25-year-old are presumably adequate. CoQ10 levels haven't significantly declined. Senescent cell burden is low. The potential benefit is therefore smaller, and the unknown long-term effects of chronically elevating these pathways from a young age are genuinely unknown. My personal view: if you're under 30 and healthy, your money is better spent on diet quality, sleep optimization, exercise consistency, and stress management — all of which have stronger evidence for long-term health than any supplement at any price point.

Interested in professional NAD+ support?

Find NAD+ IV therapy centers near you — every center is scored across our transparent methodology so you can compare providers, pricing, and protocols before you book.

NAD+ IV therapy delivers nicotinamide adenine dinucleotide directly into the bloodstream, bypassing the oral bioavailability question entirely. It's significantly more expensive than oral NMN supplementation ($200-$1,000 per session) and the clinical trial evidence for IV NAD+ is even earlier-stage than for oral NMN. But for those who want maximum NAD+ elevation with dosimetric certainty, it's the most direct route available. Our directory scores every provider on transparency, clinical oversight, and patient experience.

I'm Chad. Your chemist. And that's what the evidence actually shows — no more, no less.

Sources cited in this article (via PubMed):

• Yi L, Maier AB, Tao R, et al. The efficacy and safety of nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. DOI: 10.1007/s11357-022-00705-1 (PMID: 36482258)
• Katayoshi T, Uehata S, Nakashima N, et al. Nicotinamide mononucleotide supplementation improves metabolism and sleep in overweight adults. Endocr J. 2024;71(2):153-169. DOI: 10.1507/endocrj.EJ23-0431 (PMID: 38191197)
• Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. Safety evaluation of nicotinamide mononucleotide oral administration and its efficient increase of blood NAD+ levels. Front Nutr. 2022;9:868640. DOI: 10.3389/fnut.2022.868640 (PMID: 35479740)

Related reading:

• NAD+ IV Therapy: Complete Guide
• How a Chemist Evaluates Wellness Claims
• BDS Score Methodology: How We Rate